Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOXY: Oxytocin and Mindfulness for Smoking
NCT03819231Phase 3Terminated
- Sponsor
- University of Southern California
- Start
- Oct 2018
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of oxytocin nasal spray in nicotine dependence (3 arms), sponsored by University of Southern California. Primary endpoints: Smoking Lapse Analogue Task (delay score) and Trier Social Stress Test. Started Oct 2018; status: terminated.
02
Drugs
oxytocin nasal spray
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT03819231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03819231.